Compare Amphastar Pharmaceuticals Inc (AMPH) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Western Alliance Bancorporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.54 (market cap $826.08M), while Western Alliance Bancorporation trades at $80.32 (market cap $8.81B). The key difference: Western Alliance Bancorporation is far larger — about 10.7× Amphastar Pharmaceuticals Inc's market cap, and Western Alliance Bancorporation pays a 2.08% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | WAL | |
|---|---|---|
Market Cap | $826.08M | $8.81B |
Sector | Health | Financials |
52-Week High | $30.81 | $96.08 |
52-Week Low | $16.87 | $66.70 |
Enterprise Value | $1.22B | — |
Dividend Yield | — | 2.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Western Alliance Bancorporation (WAL) trades at $80.69, up 0.85% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals with a P/E of 9.39 and net income margin of 25.63%, supported by three consecutive quarterly earnings beats. Recent news highlights business expansion, including a $33 million Las Vegas redevelopment loan and recognition as Arizona's top bank by Forbes in 2026.
The outlook is positive given analyst consensus with a $90.67 price target and 79% buy ratings, though risks include negative operating cash flow and high interest expenses. Earnings growth and strategic hires in commercial real estate and entertainment financing present opportunities, but investor caution is warranted near technical resistance at $82.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
